Positive Results in Alzheimer’s: Are We Now Pushing the Right Buttons?

On Medical Grounds

Dr. Curtis Schreiber is the medical director at the Missouri Memory Center and was a principal investigator of a Phase III study for donanemab for patients with Alzheimer’s Disease. Many of his patients were enrolled in the trial and the encouraging results were recently released. Dr. Schreiber is with us today to discuss his work and the findings from this important study. The full read-out of the top line results for donanemab will be coming out on July 17 at an international Alzheimer’s conference followed by a publication in the Journal of the American Medical Association (JAMA) which will be linked here on release.
MISSOURI MEMORY CENTER STUDY SUMMARY:

In the phase III study, donanemab significantly slowed cognitive and functional decline in patients with early symptomatic Alzheimer’s. Results reported by
Eli Lilly & Co. include:

• 47% of participants on donanemab showed no decline based on a key measure of disease severity at one year compared to 29% of participants on placebo.

• Participants on donanemab had a 40% less decline in their ability to perform activities of daily living at 18 months.

• Participants on donanemab experienced a 39% lower risk of progressing to the next stage of disease compared to placebo.
Another Alzheimer's drug, lecanemab is expected to receive full FDA approval on July 6th. Phase III trial results showed that lecanemab slowed cognitive decline by 27%.

(00:48) Introducing Dr. Curtis Schreiber
(01:43) Optimizm for Alzheimer's treatment
(03:03) Statistical findings from phase III donanemab trial
(05:50) Participant recruitment and selection
(07:07) What is donanemab?
(08:05) Why does it work and how is it administered?
(09:19) Donanemab side effects
(13:58) How does donanemab compare to other drugs?
(15:14) Lifestyle of study participants
(16:30) Lifestyle modifications for Alzheimer's risk
(17:49) Alzheimer's genetics
(21:05) Why Dr. Schreiber switched from engineering to neurology
(22:30) His personal reason for studying Alzheimer's
(23:54) Hope for Alzheimer's
https://jamanetwork.com/journals/jama/article-abstract/2807533
Visit us at OnMedicalGrounds.com for more podcasts or download our app! You can subscribe through your podcast platform, our website, or follow us on social media for podcast updates and medical news. Some of our podcasts offer FREE CME/CE credits.
LinkTree
LinkedIn
Instagram